EBITDA Growth: Increased by more than 50% in Q1 compared to the prior year. Free Cash Flow: Outgrew the prior year level by more than 50% in Q1. Sales Record: Achieved an all-time sales record in Q1. Net Savings: High double-digit million additional net savings expected. Energy Costs: Expected to be lower due to hedges and decreasing spot energy prices. Animal Nutrition Business: Continues strong performance with tight market conditions and strong demand. Global GDP Growth Expectation: Revised down to 2.2% for 2025 from 2.5%.

Warning! GuruFocus has detected 9 Warning Sign with EVKIF.

Release Date: May 12, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Evonik Industries AG (EVKIF) reported a more than 50% increase in free cash flow in Q1 compared to the previous year. The company confirmed its full-year guidance, supported by strong Q1 performance and a solid start to Q2. Evonik's resilient businesses in specialty additives and strong growth in nutrition and care differentiate its portfolio from peers. Cost programs are in full execution, supporting solid operating performance. High local production presence shields the company from protectionism and offers opportunities behind tariff borders.

Negative Points

Global GDP growth expectations for 2025 have been lowered to 2.2%, down from 2.5% two months ago. Foreign exchange is turning from a tailwind into a headwind, impacting financial performance. There is increased uncertainty due to potential trade and tariff tensions, which could affect customer and end consumer confidence. The C4 business is experiencing macroeconomic challenges with decreasing naphtha and butadiene prices. Visibility remains low, with no significant macro slowdown yet, but potential risks such as a global recession are being monitored.

Q & A Highlights

Q: How does Evonik Industries AG plan to benefit from the upcoming infrastructure spending initiative in Germany, and what impact might Chinese exports have on the European market due to tariffs? A: Christian Kullmann, Chairman of the Executive Board, stated that the new German government is focused on making Germany and Europe attractive for the chemical industry by 2045. Evonik expects to benefit from lower energy prices and infrastructure programs, particularly in construction-related businesses. Regarding Chinese exports, Maike Schuh, CFO, noted that while there might be increased competition in crosslinkers, the impact on other products like methionine, silica, and hydrogen peroxide is expected to be limited due to Evonik's local production capabilities.

Story Continues

Q: Why did Evonik increase the discount rate for pension obligations despite declining interest rates in Europe, and is there evidence of trade uncertainty affecting the order book? A: Maike Schuh explained that the increase in the pension discount rate aligns with industry peers and is based on calculations by accountants. Christian Kullmann addressed trade uncertainty, noting that while customers are ordering in shorter terms and smaller sizes, overall volumes remain stable. There is no significant evidence of pre-buying or order stalling due to trade uncertainties.

Q: Is there any seasonal recovery expected in Q2, and what is the outlook for methionine prices? A: Maike Schuh mentioned that Evonik does not expect strong seasonality in Q2, with operations remaining stable. Christian Kullmann highlighted that methionine prices are expected to remain high due to tight market conditions and planned maintenance shutdowns by competitors, leading to a global price increase of 5% to 8%.

Q: How does Evonik view the current macroeconomic conditions and their impact on the business? A: Maike Schuh noted that while macroeconomic risks have increased, Evonik's guidance remains intact due to strong performance in Q1 and ongoing cost-saving measures. The company is prepared for potential challenges, such as trade tensions and a global recession, but currently sees no significant downturn in demand.

Q: What are the expectations for Evonik's performance in the second half of the year? A: Maike Schuh indicated that while visibility is limited, Evonik expects stable performance with continued cost savings and operational improvements. The company anticipates a strong start to the second half, particularly in the methionine business, supported by high utilization rates and strong demand.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

View Comments